AU2003237664A1 - Formulation for parenteral administration of sodium channel blockers - Google Patents
Formulation for parenteral administration of sodium channel blockersInfo
- Publication number
- AU2003237664A1 AU2003237664A1 AU2003237664A AU2003237664A AU2003237664A1 AU 2003237664 A1 AU2003237664 A1 AU 2003237664A1 AU 2003237664 A AU2003237664 A AU 2003237664A AU 2003237664 A AU2003237664 A AU 2003237664A AU 2003237664 A1 AU2003237664 A1 AU 2003237664A1
- Authority
- AU
- Australia
- Prior art keywords
- formulation
- parenteral administration
- sodium channel
- channel blockers
- blockers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 238000007911 parenteral administration Methods 0.000 title 1
- 239000003195 sodium channel blocking agent Substances 0.000 title 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Nanotechnology (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10223783A DE10223783A1 (de) | 2002-05-29 | 2002-05-29 | Neue Formulierung zur parenteralen Applikation eines Na-Kanal-Blockers |
| DE10223783.2 | 2002-05-29 | ||
| PCT/EP2003/005399 WO2003099336A1 (de) | 2002-05-29 | 2003-05-23 | Formulierung zur parenteralen applikation eines na-kanal-blockers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2003237664A1 true AU2003237664A1 (en) | 2003-12-12 |
Family
ID=29432393
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2003237664A Abandoned AU2003237664A1 (en) | 2002-05-29 | 2003-05-23 | Formulation for parenteral administration of sodium channel blockers |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP1511517B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2005527615A (cg-RX-API-DMAC7.html) |
| AR (1) | AR040134A1 (cg-RX-API-DMAC7.html) |
| AT (1) | ATE373492T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2003237664A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2487150A1 (cg-RX-API-DMAC7.html) |
| DE (2) | DE10223783A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2294295T3 (cg-RX-API-DMAC7.html) |
| PE (1) | PE20040066A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW200400029A (cg-RX-API-DMAC7.html) |
| UY (1) | UY27823A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2003099336A1 (cg-RX-API-DMAC7.html) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4239877C1 (de) * | 1992-11-27 | 1994-03-17 | Boehringer Ingelheim Int | Stabilisierte Superoxid-Dismutase (SOD)-Zusammensetzung |
| DE4313408A1 (de) * | 1993-04-23 | 1994-10-27 | Boehringer Mannheim Gmbh | Cyclodextrin-Biocid-Komplex |
| FR2713934B1 (fr) * | 1993-12-22 | 1996-01-12 | Commissariat Energie Atomique | Utilisation de cyclodextrines aminées pour la solubilisation aqueuse de composés hydrophobes, en particulier de molécules pharmaceutiquement actives. |
| DE19740110A1 (de) * | 1997-09-12 | 1999-03-18 | Boehringer Ingelheim Pharma | Substituierte 1,2,3,4,5,6-Hexahydro-2,6-methano-3-benzazocin-10-ole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| US6565880B2 (en) * | 2000-07-24 | 2003-05-20 | Boehringer Ingelheim Pharmaceuticals, Inc. | Oral dosage formulations of 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea |
| DE10223784A1 (de) * | 2002-05-29 | 2003-12-11 | Boehringer Ingelheim Pharma | Neue Formulierung zur parenteralen Applikation von Crobenetine |
-
2002
- 2002-05-29 DE DE10223783A patent/DE10223783A1/de not_active Withdrawn
-
2003
- 2003-05-23 AU AU2003237664A patent/AU2003237664A1/en not_active Abandoned
- 2003-05-23 EP EP03735445A patent/EP1511517B1/de not_active Expired - Lifetime
- 2003-05-23 CA CA002487150A patent/CA2487150A1/en not_active Abandoned
- 2003-05-23 WO PCT/EP2003/005399 patent/WO2003099336A1/de not_active Ceased
- 2003-05-23 JP JP2004506859A patent/JP2005527615A/ja active Pending
- 2003-05-23 DE DE50308227T patent/DE50308227D1/de not_active Expired - Fee Related
- 2003-05-23 ES ES03735445T patent/ES2294295T3/es not_active Expired - Lifetime
- 2003-05-23 AT AT03735445T patent/ATE373492T1/de not_active IP Right Cessation
- 2003-05-27 PE PE2003000511A patent/PE20040066A1/es not_active Application Discontinuation
- 2003-05-27 UY UY27823A patent/UY27823A1/es not_active Application Discontinuation
- 2003-05-28 TW TW092114414A patent/TW200400029A/zh unknown
- 2003-05-28 AR ARP030101863A patent/AR040134A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| DE50308227D1 (de) | 2007-10-31 |
| DE10223783A1 (de) | 2003-12-11 |
| EP1511517A1 (de) | 2005-03-09 |
| ES2294295T3 (es) | 2008-04-01 |
| JP2005527615A (ja) | 2005-09-15 |
| EP1511517B1 (de) | 2007-09-19 |
| PE20040066A1 (es) | 2004-03-22 |
| ATE373492T1 (de) | 2007-10-15 |
| WO2003099336A1 (de) | 2003-12-04 |
| AR040134A1 (es) | 2005-03-16 |
| CA2487150A1 (en) | 2003-12-04 |
| UY27823A1 (es) | 2003-12-31 |
| TW200400029A (en) | 2004-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2003302540A1 (en) | Synchronization of signals | |
| AU2003272590A1 (en) | Method for ophtalmic administration of medicament | |
| AU2003296897A1 (en) | Pharmaceutical formulations of camptothecine derivatives | |
| AU2003268087A1 (en) | Liposomal gemcitabine compositions for better drug delivery | |
| AU2003276323A1 (en) | Arranging synchronization session | |
| AU2003224969A1 (en) | Radio interface synchronization | |
| AU2003248122A1 (en) | Sodium channel inhibitor | |
| AU2002353180A1 (en) | Use of ugt inhibitors to increase bioavailability | |
| AU2003226189A1 (en) | Oral administration of epothilones | |
| AU2003272355A1 (en) | Telecommunications interface | |
| AU2003250317A1 (en) | Device for administration of fluids | |
| AU2003224781A1 (en) | Crystalline forms of rabeprazole sodium | |
| AU2003297693A1 (en) | Splice variant of human sodium iii channel (hnaiii18) | |
| IL161560A0 (en) | Anthelmintic compositions containing milbemycin derivatives | |
| AU2002338201A1 (en) | Anthelmintic composition | |
| AU2003900505A0 (en) | Anthelmintic composition | |
| AU2003279392A1 (en) | Pharmaceutical compositions of azithromycin | |
| AU2003237664A1 (en) | Formulation for parenteral administration of sodium channel blockers | |
| AU2002343199A1 (en) | Formulations of erythromycin derivatives with improved bioavailability | |
| AU2003300543A1 (en) | Slow release formulation of clarithromycin | |
| AU2003229459A1 (en) | Methods of using thiazolidinedithione derivatives | |
| AU2003225745A1 (en) | Free-base formulations of local anesthetics | |
| AU2003237224A1 (en) | 1,2 diamido cycloalkyl sodium channel blockers | |
| AU2003298725A1 (en) | Preparation of metallotexaphyrins | |
| AU2003285790A1 (en) | Engaging structure of assistant glasses for glasses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |